
Reconnect Labs pursues precision neuropsychiatry to treat mental health conditions with targeted therapies. It combines advanced therapeutics with AI-driven companion diagnostics to enable rapid symptom relief and disease modification. The approach leverages psychedelic science, neuroscience, psychopharmacology, and digital psychiatry tools as core technologies. As a clinical-stage biopharmaceutical company, it collaborates with academic partners such as the University of Zurich to advance its pipeline.

Reconnect Labs pursues precision neuropsychiatry to treat mental health conditions with targeted therapies. It combines advanced therapeutics with AI-driven companion diagnostics to enable rapid symptom relief and disease modification. The approach leverages psychedelic science, neuroscience, psychopharmacology, and digital psychiatry tools as core technologies. As a clinical-stage biopharmaceutical company, it collaborates with academic partners such as the University of Zurich to advance its pipeline.